Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 7Lymphoma 6Lymphoma, Follicular 5Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Biphenotypic, Acute 3Dendritic Cell Sarcoma, Interdigitating 3Congenital Abnormalities 3Blast Crisis 3Sezary Syndrome 2Sarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Mycosis Fungoides 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Methylprednisolone × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡